Maxim Group
http://www.maximgrp.com/Maxim Group is a financial services firm that provides investment banking, asset management, research, and sales & trading to a diverse range of corporate clients, institutional investors and high net worth individuals.
The firm’s research division uses fundamental research and a “bottom up” approach to making investment recommendations. Maxim’s research analysts focus on under-covered, small- to mid-cap names in a variety of sectors including healthcare, technology, retail and others.
View Older Stories View More Recent Stories
-
Joseph Gunnar & Co., LLC is pleased to announce the hiring of Ashok Kumar to Head its Equity Research Department
-
Cytori Extends Rights Offering Subscription Period to Friday, June 10, and Adjusts Unit Pricing
-
Maxim Positive on BrainStorm Cell Therapeutics (BCLI) into Upcoming NurOwn Phase 2 Data in ALS; Affirms at 'Buy'
-
Notable Analyst Rating Changes 6/3: (UNP) (DE) (WFT) Upgraded; (ICLR) (TSL) (PCAR) Downgraded
-
Maxim Group Starts Yelp (YELP) at Buy
-
Maxim Group Starts GrubHub Inc. (GRUB) at Buy
-
Maxim Group Upgrades EnerSys (ENS) to Buy
-
Onconova Files S-1 Registration Statement for Rights Offering to Shareholders
-
Maxim Group Says Galena Biopharma (GALE) Fast Track is Positive and Further Validates NeuVax Potential
-
Maxim Group Downgrades StemCells (STEM) to Hold
-
ContraVir Pharma (CTRV) Gains Key Preclinical Antiviral Asset with Ciclofilin Pharna Deal; Maxim Affirms at 'Buy'
-
Propanc Engages Two Advisory Firms to Identify Strategic Partnering Opportunities
-
Cytori Announces Commencement of Subscription Period for Previously Announced Rights Offering
-
Reed's (REED) Enters $2.2M Common Stock, Warrants Private Placement
-
Arch Therapeutics Announces May 26, 2016 $3.4 Million Private Placement
-
Reed’s Announces $2.2 Million Private Placement
-
OncoSec Closes $10 Million At-The-Market Registered Direct Offering
-
Notable Analyst Rating Changes 5/26: (ADM) (INFY) (SKIS) Upgraded; (HBAN) (NWN) (USDP) Downgraded
-
Arlington Asset Investment Corp. Issues Letter Urging Shareholders To Protect Their Dividend And Investment
-
Maxim Group Starts Shopify (SHOP) at Hold
-
Maxim Group Downgrades Oxford Lane (OXLC) to Sell
-
Maxim Group Starts Wayfair (W) at Buy
-
Maxim Group Starts Overstock.com (OSTK) at Buy
-
Maxim Group Starts Etsy (ETSY) at Buy
-
Opexa (OPXA) SPMS Data in September Could Signal The First Therapy in a $7B Mkt - Maxim
-
Notable Analyst Rating Changes 5/24: (SQ) (MSFT) (DE) Upgraded; (TWTR) (CF) (CYH) Downgraded
-
Pre-Open Stock Movers 05/24: (MGN) (XCO) (PLCM) (GPRO) Higher; (SSW) (DSW) (SAGE) (BBY) Lower (more...)
-
Maxim Group Upgrades Fifth Street Finance (FSC) to Hold
-
Maxim Group Starts Viking Therapeutic (VKTX) at Buy
-
Maxim Group Starts CytoSorbents (CTSO) at Buy
-
OpGen Announces Closing of $10 Million Private Placement
-
AssuredPartners Acquires MaximGroup
-
Vivint Smart Home to Keynote Parks Associates' 20th Annual CONNECTIONS(TM) Conference
-
Notable Analyst Rating Changes 5/17: (HAL) (CFX) (FCX) Upgraded; (HIG) (GST) (ANAC) Downgraded
-
Maxim Group Starts Bob Evans Farms (BOBE) at Buy
-
NAPCO Security Bolsters its Investor Relations Efforts
-
Cytori Informs Stockholders of Key Dates Related to Announced Rights Offering
-
Maxim Group Reiterates Bullish View on Inovio (INO) as Zika Vaccine Moves Closer to Human Trials
-
Prima Biomed (PBMD) PT Raised to $5 at Maxim Group Amid CVac Partnership
-
Maxim Group Bullish on Galena Biopharma (GALE) Into Interim Analysis of PRESENT Study
-
IsoRay (ISR) in a Strong Position to Execute on Cesium-131 - Maxim Group
-
Notable Analyst Rating Changes 5/6: (ARIA) (MAC) (GM) Upgraded; (FRT) (WMB) (ZTS) Downgraded
-
Maxim Group Starts ContraVir Pharma (CTRV) at Buy
-
Medivation (MDVN) PT Raised to $76 at Maxim Group with Shares 'In Play'
-
ADMA Biologics Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Parks Associates: 27% of U.S. Car Owners Want Their Car to Be Able to Connect to Their Smart Home Devices
-
Maxim Group Upgrades Intevac (IVAC) to Buy
-
Viking Therapeutics Announces Full Exercise of Over-Allotment Option
-
Maxim Group Downgrades Gilead Sciences (GILD) to Hold
-
ADMA Biologics (ADMA) Prices 1.89M Common Stock Offering at $6.50/Share

